加速型甲氨蝶呤、长春碱、多柔比星与顺铂新辅助化疗用于肌层浸润性膀胱癌患者:按年龄分层的安全性与疗效回顾性分析
该回顾性分析纳入2002年1月1日至2018年12月31日在Fox Chase癌症中心治疗的186例肌层浸润性膀胱癌患者,按年龄(<65岁、65-74岁、>75岁)分层评估新辅助加速型甲氨蝶呤、长春碱、多柔比星与顺铂(aMVAC)的安全性与疗效。单变量和多变量分析显示,各年龄组在剂量减少、治疗中断、手术时间或不良事件方面无统计学显著差异;老年患者基线肾功能显著更差,且肌酐清除率下降百分比随年龄增长而更大。aMVAC的疗效不受年龄影响。
要点
- 各年龄组在剂量减少、治疗中断、手术时间或不良事件方面无统计学显著差异。
- 老年患者基线肾功能显著更差,肌酐清除率下降百分比随年龄增长而更大。
- aMVAC的疗效不受年龄影响,但研究为单中心回顾性分析。
核心结论
- 在这项单中心回顾性研究中,加速型MVAC在肌层浸润性膀胱癌患者中安全且有效,与年龄无关。
- 基于临床变量而非年龄的仔细选择应能识别出适合接受新辅助化疗的患者。
研究设计与样本
- 回顾性分析,纳入2002年1月1日至2018年12月31日在Fox Chase癌症中心治疗的186例肌层浸润性膀胱癌患者。
- 纳入组织学证实的肌层浸润性尿路上皮癌成人患者;排除非尿路上皮组织学、缺乏固有肌层浸润、原发性上尿路或转移性疾病。
- 患者按年龄分层(<65岁、65-74岁、>75岁)。
- 干预为新辅助加速型甲氨蝶呤、长春碱、多柔比星与顺铂(aMVAC)化疗。
主要发现
- 单变量和多变量分析中,按年龄分层后,剂量减少、治疗中断、手术时间或不良事件均无统计学显著差异。
- 老年患者基线肾功能显著更差,且肌酐清除率下降百分比随年龄增长而更大。
- 无论年龄如何,aMVAC的疗效相当。
临床怎么用
- 作者认为,基于临床变量而非年龄的仔细选择应能识别出适合接受新辅助化疗的患者。
局限性
- 由于研究的回顾性性质,完整的安全性数据不可获得。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The standard of care (SOC) for muscle-invasive bladder cancer (MIBC) includes cisplatin-based combination chemotherapy in the neoadjuvant setting followed by radical cystectomy. Older patients often do not receive SOC due to perceived toxicity concerns despite guideline-directed recommendations. OBJECTIVE: To characterize the safety and efficacy of neoadjuvant accelerated methotrexate, vinblastine, adriamycin, and cisplatin (aMVAC) in MIBC patients as a function of age. DESIGN, SETTING, AND PARTICIPANTS: A retrospective analysis was conducted in 186 MIBC patients treated at Fox Chase Cancer Center between January 1, 2002 and December 31, 2018. Adults with histologically proven muscle-invasive urothelial cancer were eligible. The exclusion criteria included nonurothelial histology, lack of muscularis propria invasion, and primary upper tract or metastatic disease. INTERVENTION: Neoadjuvant chemotherapy with aMVAC. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Patients were stratified by age (<65, 65-74, and >75 yr old). Renal function was assessed at baseline and at time points after treatment. Clinicopathologic variables were compared between age groups to determine efficacy. RESULTS AND LIMITATIONS: There were no statistically significant differences in dose reductions, treatment interruptions, time to surgery, or adverse events when patients were stratified by age in univariate and multivariate analyses. Full safety data were not available due to the retrospective nature of the study. Baseline renal function was significantly worse among older patients, and the percent decline in creatinine clearance was greater with older age. We found comparable efficacy of aMVAC regardless of age. CONCLUSIONS: Accelerated MVAC was safe and demonstrated efficacy in MIBC irrespective of age in this single-center, retrospective study. Careful selection based on clinical variables, and not age, should identify patients able to receive neoadjuvant chemotherapy. PATIENT SUMMARY: We examined the feasibility of the standard cisplatin-based chemotherapy regimen given prior to surgery in patients with muscle-invasive bladder cancer. Elderly patients experienced a greater decline in kidney function with treatment but not more complications than younger patients and tolerated therapy with minimal dose changes, resulting in benefit regardless of age.
引用
- Hemenway G, Lewis B, Ghatalia P, et al. Neoadjuvant Chemotherapy with Accelerated Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Patients with Muscle-invasive Bladder Cancer: A Retrospective Age-stratified Analysis on Safety and Efficacy. Eur Urol Oncol. 2022. PMID: 35792045. doi:10.1016/j.euo.2022.06.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。